美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Kailera Therapeutics, Inc.

16.00

0.0000

成交量：- -

成交額：- -

市值：18.87億

市盈率：- -

高：- -

開：- -

低：- -

收：16.00

52周最高：- -

52周最低：- -

股本：1.18億

流通股本：3,333.33萬

量比：- -

換手率：- -

股息：- -

股息率：- -

淨資產收益率：-36.90%

總資產收益率：-22.73%

市淨率：-5.29

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Kailera Therapeutics, Inc.

交易所：

NASDAQ

成立時間：

2024

員工人數：

145

公司地址：

180 Third Avenue,4th Floor,Waltham,Massachusetts,United States

官網：

http://www.kailera.com

郵編：

02451

電話：

傳真：

- -

簡介：

Kailera Therapeutics, Inc.於2024年5月8日根據特拉華州法律註冊成立。該公司是一家處於臨床階段的生物技術公司，致力於通過推進多元化的研發管線，引領肥胖症治療的新時代。目前，該公司正在快速推進四款處於臨床階段的候選產品，這些產品利用多種基於胰高血糖素樣肽-1 (GLP-1) 的作用機制和給藥途徑。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/KLRA/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics, Inc.","latestPrice":16,"timestamp":1776369600000,"preClose":16,"halted":9,"volume":0,"delay":0,"changeRate":0,"floatShares":33333334,"shares":117948773,"eps":0,"marketStatus":"待開盤","change":0,"latestTime":"04-16 16:00:00 EDT","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1776432600000},"marketStatusCode":16,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":16,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","floatShares":33333334,"roa":"-22.73%","roe":"-36.90%","lyrEps":0,"shares":117948773,"dividePrice":0,"high":0,"amplitude":0,"preClose":16,"low":0,"week52Low":0,"pbRate":"-5.29","week52High":0,"institutionHeld":0,"latestPrice":16,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRA","date":"2026-04-16","current":-11.877625,"percent":1,"low":-11.877625,"twenty":-11.877625,"median":-11.877625,"eighty":-11.877625,"high":-11.877625,"avg":-11.877625,"sd":0,"marketCap":1769231595},"quantilePoints":[{"date":"2026-04-16","current":-11.877625,"twenty":-11.877625,"median":-11.877625,"eighty":-11.877625,"marketCap":1769231595}],"updateTime":1776417822448},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1899116257,"yearFounded":2024,"employeeNum":145,"address":"180 Third Avenue,4th Floor,Waltham,Massachusetts,United States","zipCode":"02451","officePhone":"(781) 317-0290"},"stockCompanyDetail":{"websiteUrl":"http://www.kailera.com","compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Kailera Therapeutics, Inc.於2024年5月8日根據特拉華州法律註冊成立。該公司是一家處於臨床階段的生物技術公司，致力於通過推進多元化的研發管線，引領肥胖症治療的新時代。目前，該公司正在快速推進四款處於臨床階段的候選產品，這些產品利用多種基於胰高血糖素樣肽-1 (GLP-1) 的作用機制和給藥途徑。","exchange":"NASDAQ","name":"Kailera Therapeutics, Inc.","nameEN":"Kailera Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":null}}